Silence Therapeutics (SLN) H.C. Wainwright 4th Annual BioConnect Investor Conference summary

Pipeline overview and value drivers

• Focus on siRNA-based precision medicines using the mRNAi GOLD Platform, targeting cardiometabolic and hematological diseases.

• Key clinical assets include divesiran (polycythemia vera), zerlasiran (Lp(a) for cardiovascular disease), and SLN312 (dyslipidemia).

• Phase II SANRECO data for divesiran and phase III readiness for zerlasiran expected in August 2026.

• SLN312 phase I data to be presented at EAS, with phase II readiness anticipated.

• Early-stage pipeline includes SLN365 (hypercholesterolemia) and SLN098 (obesity), with ongoing preclinical work and partnership opportunities.

RNAi technology and differentiation

• siRNA enables targeting of previously undruggable genes with high potency and long duration of effect.

• Dosing can be infrequent (every 3 months or longer), improving patient convenience.

• Proprietary chemistry and linker technology enhance stability and activity.

• Open to partnerships to advance development and leverage external expertise.

Divesiran for polycythemia vera

• Targets TMPRSS6 to increase hepcidin, reducing iron availability and controlling hematocrit.

• Phase II SANRECO trial fully enrolled, with 48 patients across placebo and two dosing regimens (6-week and 12-week).

• Primary endpoint: proportion of responders with hematocrit <45% without phlebotomy between weeks 18-36.

• Phase I data showed durable hematocrit control and safety up to 9 mg/kg.

• Quality of life and durability data to be presented at EHA; 6-week dosing seen as commercially compelling.